Cannabidiol for Pain Relief of Patients With End-stage mCRPC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical trial is to evaluate the effects of cannabidiol in patients with end-stage metastatic castration-resistant prostate cancer (mCRPC). The primary objective is to determine whether cannabidiol (CBD) treatment can reduce the need for opioids in patients with end-stage mCRPC. Additionally, the study will assess a range of clinical endpoints in patients with end-stage mCRPC, including: 1. The efficacy of CBD treatment in alleviating pain 2. The efficacy of CBD treatment in reducing the need for non-opioid medications and concomitant therapies 3. The impact of CBD treatment on physical activity and quality of life 4. The anti-inflammatory and potential anti-tumor properties of CBD 5. The safety of CBD treatment Patients from Department of Urology, Aalborg University Hospital will be included. Participants will be treated with either CBD (200 mg) or placebo (0 mg) three times daily for nine weeks. At baseline, halfway and end of trial, participants will use an activity tracker and complete questionnaires regarding pain and quality of life and provide blood samples to measure inflammation and tumor activity. Also, they will complete a daily dairy regarding the study drug and intake of pain medication. Adverse events will be assessed by Common Terminology Criteria for Adverse Events.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznanie zaawansowanego raka prostaty opornego na standardowe leczenie (castration-resistant prostate cancer)
- •Brak innych dostępnych opcji leczenia lub niezdolność do poddania się standardowej terapii
- •Występowanie bólu
- •Codzienne stosowanie morfiny (co najmniej 20 mg dziennie) w celu złagodzenia bólu
✗ Disqualifies
- •Brak wystarczającego bólu do włączenia do badania (poniżej 4 punktów w skali bólu)
- •Historia krótkiego okresu odpowiadania na poprzednie leczenia (poniżej 6 miesięcy)
- •Poważne problemy z wątrobą lub nerkami
- •Zaburzenia serca lub płuc w poważnym stopniu
- •Stosowanie produktów zawierających THC (cannabis) w ostatnim czasie
- •Historia uzależnienia od substancji psychoaktywnych
- •Alergия na kannabidiol
- •Brak zdolności do wyrażenia świadomej zgody lub nieznajomość języka duńskiego
Simplified criteria — AI translation
Trial details
- Last updated (source)
- August 7, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
Department of Urology, Aalborg University Hospital
Gistrup, Denmark
Trial contact
Peter Derek Christian Leutscher
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.